Chronic hepatitis B virus (HBV) infection is closely related to the development of severe liver complications, including hepatocellular carcinoma. In previous studies, we reported that in vivo long-term HBV suppression in transgenic mice can be achieved without apparent toxicity by short hairpin RNA sequentially delivered using adeno-associated viral (AAV) vectors of different serotypes. Our goal herein was to address the clinical utility of this delivery system and, in particular, to determine whether RNA interference (RNAi) and its ability to induce long-term HBV suppression will modulate the development of HBV-associated liver pathology. As a model system, we used a unique HBV transgenic mouse model, containing a 1.3 times over length of the HBV genome, on the ICR mouse background. These transgenic mice produce high serum HBV titers comparable with human chronic HBV patients, and, importantly, manifest characteristic HBV-associated pathology, including progressive hepatocellular injury and the development of hepatocellular adenoma. Using this system, we injected animals with AAV vectors expressing either HBV-specific or a control luciferase-specific short hairpin RNA and followed animals for a total of 18 months. We report herein that AAV-mediated RNAi therapy profoundly inhibits HBV replication and gene expression, with a significant reduction in hepatic regeneration, liver enzymes and, importantly, the appearance of liver adenomas. Indeed, the therapeutic effect of RNAi correlated with the reduction in HBV titers. Our data demonstrate that appropriately designed RNAi therapy has the potential to prevent formation of HBV-associated hepatocellular adenoma.
INTRODUCTION
Approximately 400 million people worldwide are chronically infected with hepatitis B virus (HBV), and a significant proportion of these patients ultimately develop liver failure, cirrhosis and hepatocellular carcinoma (HCC). 1,2 Several studies of large cohorts of HBV carriers have demonstrated that serum HBV DNA levels are highly correlated with disease development, 3, 4 suggesting that long-term inhibition of HBV replication might benefit patients by preventing occurrence of severe hepatic complications. Although currently available antiviral drugs have shown potential in preventing liver disease progression, 5, 6 the durable therapeutic effects are severely limited by emergence of drug-resistant mutants. 7 RNA interference (RNAi) therapy using chemically synthesized small interfering RNA and plasmid-or adenovirus-encoded small hairpin RNA (shRNA) have shown promising anti-HBV effects in cell cultures 8, 9 and animal models. [10] [11] [12] However, because of the transient nature of the suppression and the inefficient liver transduction rate, these approaches are unlikely to generate durable anti-HBV effects in more stringent HBV infection conditions, such as in chronically infected patients, as virtually all hepatocytes are infected. We have previously reported generation of a transgenic murine model carrying a complete HBV genome on the ICR mouse background (denoted hereafter ICR/HBV), and demonstrated that, throughout their lifetime, these mice produced consistently high levels of serum HBV DNA, with titers comparable with those found in chronic HBV patients. 13 We demonstrated that administration of a double-stranded adeno-associated virus serotype 8 vector (dsAAV8), encoding a HBVtargeting shRNA, profoundly reduced the serum HBV titer and the liver HBV DNA, mRNA and proteins for at least 120 days without apparent toxicities. 13 However, the RNAi effect gradually decreased with time, presumably because of the liver injury and subsequent liver regeneration in the aged ICR/HBV mice. 14 A longer anti-HBV effect can be achieved by the sequential use of AAV vectors of different serotypes expressing the same anti-HBV shRNA. 14 An important follow-up question is whether long-term RNAi therapy could prevent occurrence of HBV-associated diseases.
RESULTS
Liver pathological changes and development of hepatocellular adenoma in ICR/HBV transgenic mice ICR/HBV mice were previously generated by microinjection of ICR embryos with a DNA fragment 1.3 times the size of the HBV genome. 13 To recapitulate the validity of the model, several basic features of this transgenic mouse line were studied. For example, Northern blotting analysis revealed significant levels of HBV mRNAs in the liver and kidney (Figure 1a) . Likewise, HBV replicative DNA, including relaxed circular, double-and single-stranded DNA, was found in these organs (Figure 1b) . Immunohistochemistry analysis showed that HBV core antigen expression was seen in the nucleus of most hepatocytes and in the cytoplasm of the centrilobular hepatocytes ( Figure 1c ). HBV core antigen was also detected in the cortex, but not the medulla of the kidney in transgenic mice (Figure 1c ), as in a previous report. 15 These transgenic animals also secreted high levels of viral proteins and virions into the circulation. The amounts of serum HBV surface antigen (HBsAg) was much higher in male mice than in female mice (signal-to-noise ratio of 25.6±8.7 and 14.5±6.2, respectively, P¼0.019; Figure 1d ). Similarly, serum HBV titers were more homogenous and higher in male mice (average titer of 1.6Â10 8 copies ml À1 ) than in females (average titer of 6.8Â10 7 copies ml À1 , P¼0.04; Figure 1e ). The level of HBV virions in the circulation of transgenic mice was comparable with that in chronically infected patients ( Figure 1e ) and was stably maintained for at least 18 months (see Figure 4b ). We also found that HBV e antigen was higher in male mice (signal-to-noise ratio of 14.5 ± 6.2) than in female mice (signalto-noise ratio of 11.3 ± 8.7), but the difference was not statistically significant ( Figure 1d ). We did not find detectable antibodies against HBsAg and HBV e antigen across the 18-month observation period, suggesting that these transgenic mice were immune tolerance to HBV.
To investigate the long-term consequences of HBV-laden hepatocytes, serum alanine aminotransferase (ALT) levels, an indicator of liver injury, was measured in male ICR/HBV mice of different ages. Between the ages of 2 and 8 months, serum ALT levels in ICR/HBV mice were similar to those in their non-transgenic littermates (data not shown). Thereafter, ALT levels in the transgenic mice gradually increased from 66±27 IU l À1 at 10 months of age (n¼11) to 110±39 IU l À1 at 15 months of age (n¼6; Figure 2a ). In contrast, serum ALT of non-transgenic littermates remained constant across the 15-month observation period (42 ± 23 and 41 ± 14 IU l À1 at 10 and 15 months of age, respectively).
In accordance with the ALT result, clear liver histological changes were seen in male ICR/HBV transgenic mice at 8-10 months of age and became more severe in older mice. Representative histopathological features of ICR/HBV mice between the ages of 12 and 14 months are shown in Figure 2b (panels 2-4), with liver sections of a non-transgenic littermate of the same age as a control (Figure 2b , panel 1). In the ICR/HBV mouse liver, it was common to see acidophilic nuclear inclusions, which pushed the nucleoli aside and led to enlargement of the nuclei (Figure 2b, panel 2) . Ultrastructural analysis revealed that the enlarged nuclei were filled with 20-22 nm nucleocapsid particles (Figure 2b , panel 2, inset), resembling those found in similar HBV transgenic or infected animal models and in chronic HBV patients. 15, 16 Swollen hepatocytes with various sizes of cytoplasmic vacuolations (Figure 2b , panel 3) and features of individual hepatocyte coagulative necrosis (Figure 2b , panel 4) demonstrated degenerative changes. In contrast, the non-transgenic mice did not show overt hepatic lesions (Figure 2b, panel 1) . At the age of 18 months, 470% of these male ICR/HBV mice developed multiple macroscopically visible liver nodules, ranging from 4 mm to 420 mm in diameter (summary data from 420 mice of different experiments, Figure 3a and Table 1 ). Microscopic examination revealed prominent mitotic figures in the livers of nodule-bearing mice (Figure 3b, panel 1) .
The nodules were composed of disorganized hepatic plates made up of hepatocytes with less amount of cytoplasm and relatively hyperchromatic nuclei characterized as small cell transformation ( Figure 3b , panel 2) and hyperplastic regeneration (Figure 3b, panel 3 ). These liver nodules were therefore classified as hepatocellular adenomas. Similar to the less liver cancer incidence found in female than in male HBV patients, we also found that the frequency of liver adenoma rate is much lower in female than in male ICR/HBV mice, with only 20% (1 of 5) of female mice developing macroscopically visible liver nodules at the age of 18 months compared with 470% in male mice. Histological analysis revealed little or no mononuclear cell infiltration in the liver over the 18-month observation period. This is an expected result because of the anticipated inherent immune tolerance to HBV antigens in HBV transgenic mice. 17, 18 Prevention of HBV-associated adenoma formation by long-term RNAi therapy To investigate the effect of long-term RNAi therapy on HBVassociated liver pathology, we used HBV-S1 shRNA to construct pseudotyped dsAAV vectors of serotype 7, 8 and 9, which have been shown to transduce the mouse liver with high efficacy. 14 We used HBV-S1 shRNA in this experiment, because HBV-S1, but not other HBV-specific shRNAs, delivered by these hepatotropic AAV vectors effectively suppresses HBV replication and gene expression in the ICR/HBV transgenic mouse model without apparent toxicities. 13, 14 Our previous data showed that the dsAAV7, 8 and 9 were not crossreactive, and a longer anti-HBV effect could be achieved by the sequential use of dsAAV8/HBV-S1 and dsAAV9/HBV-S1. 14 Groups of viral titer-matched 6-week-old HBV transgenic mice were sequentially injected intravenously with the distinct AAV serotypes carrying HBV-S1 or the control luciferase-specific GL2 shRNA at the time points shown in Figure 4a . To evaluate the influence of RNAi treatment on liver pathology, male HBV transgenic mice were used here because of higher incidence of liver adenoma in this gender. HBV transgenic mice injected with saline were also included as a control. In the first experiment, mice were administered with 1Â10 12 vector genome (vg) of dsAAV vectors for each injection. At this dosage, the first injection of dsAAV8/HBV-S1 resulted in a profound suppression of serum HBV titer (6200-fold reduction of the mean titer of viral DNA at 3 weeks post injection Figure 4b ), but the second injection of dsAAV9 and the third injection of dsAAV7 expressing the same HBV-S1 shRNA led only to a slight and transient reduction in HBV titer. The inefficiency of RNAi-mediated suppression of HBV at later time points is probably because of the the suboptimal dosage of dsAAV vectors (1Â10 12 vg per mouse) given at this age (47 weeks of age for the second injection and 62 weeks of age for the third injection) when mice grew to a much heavier body weight (an average of two times heavier than the 6-week-old mice when receiving the first AAV injection). In the second experiment, we applied dsAAV vectors according to the body weight of the treated animals at a dose of 3.3Â10 13 vg kg À1 . In this set of experiment, sequential treatment of transgenic mice with dsAAV vectors expressing HBV-S1 shRNA resulted in profound and sustained anti-HBV effects in both the first and second treatments. The kinetics of the suppression of serum HBV DNA levels in experiment 2 is shown (Figure 4c ). After the initial dsAAV8/HBV-S1 treatment, HBV expressions were profoundly reduced within 1 week and reached a minimum at 3-4 weeks post injection (9-10 weeks of age), with an average reduction in viral DNA levels of 3847-fold. The strength of RNAi suppression then gradually decreased with time, presumably because of the loss of AAV vectors in the liver. 13 A second injection with dsAAV9/HBV-S1 at the age of 62 weeks caused a similar level of HBV suppression as the first treatment and prolonged HBV suppression in these transgenic animals ( Figure 4c ). Mice injected with saline or dsAAV vector of the same serotype, but expressing the irrelevant GL2 shRNA, showed no change in serum HBV DNA titer over the 17-month observation period (Figures 4b and c) .
These animals were killed at 18 months of age to investigate the long-term effect of RNAi treatment on liver adenoma formation. We found that sustained HBV suppression greatly reduced the incidence of liver adenomas in transgenic mice. Only 4 of 11 mice (36%, P¼0.04) in the HBV-S1 shRNA-treated group (Figure 5a , upper panel, combined results from two experiments) developed macroscopically detectable nodules, which was significantly lower compared with the saline group (75%, 12 of 16 mice). In contrast, mice treated with the control GL2 shRNA did not protect HBV transgenic mice from developing liver adenomas (71%, 5 of 7 mice, P¼0.86 versus the saline group). Moreover, HBV-S1-treated mice tended to have smaller adenomas compared with those in the saline or GL2 groups (Figure 5b, arrowheads) , although the sample size in the HBV-S1 group (only 4 of 11 mice developed adenomas) is too small for us to do statistical analysis. The detail information of these data, including the number of liver nodules, the size of the largest nodule, and the concentration of serum ALT and alkaline phosphatase, is provided in the Table 1 . No liver adenomas were observed in age-and sex-matched transgene negative littermates (zero of eight mice). The anti-adenoma effect of RNAi therapy was further proved by its ability to prevent the increase in the relative liver weight in HBV transgenic mice to the levels found in the transgene negative littermates (4.6 ± 0.8% in HBV-S1-treated transgenic mice versus 3.9±0.6% in transgene negative mice, P¼0.07; Figure 5a , lower panel), whereas transgenic mice in the saline and GL2 shRNA-treated groups had much higher relative liver weights (7.0 ± 2.5%, P¼0.003 and 6.6 ± 1.7%, P¼0.02, respectively).
Interestingly, we noticed that those HBV-S1-treated mice that did develop adenomas, showed a lower response to RNAi treatment. For example, in experiment 1 dsAAV8/HBV-S1 treatment failed to protect 50% of mice from developing liver adenomas, and the adenoma-bearing mice (Figure 5c , empty circles) demonstrated much shorter and less potent HBV suppression compared with the adenoma-free mice (Figure 5c, filled circles) . Kinetic analysis showed that the initial dsAAV8/HBV-S1 treatment reduced the serum HBV titer in the adenoma-bearing and adenoma-free mice from an average of 3.5Â10 8 and 2.1Â10 8 copies ml À1 , respectively, to 8.2Â10 5 and 6.9Â10 5 copies ml À1 . Thereafter, the HBV titer in the adenomabearing mice showed a more rapid increase and was maintained at much higher level than that of the adenoma-free mice. For example, at 30 weeks of age the two mice in the adenoma group carried 1.0Â10 8 and 3.3Â10 7 copies ml À1 of serum HBV, significantly higher than the titer of 5.2Â10 5 and 7.8Â10 6 copies ml À1 in the animals in the nonadenoma group. A second injection of dsAAV9/HBV-S1 and a third injection of dsAAV7/HBV-S1 did not significantly reduced HBV titers (Figure 5c ), probably because of the suboptimal dosage of dsAAV vector used in this experiment as discussed above. As a result, the mice that eventually developed adenomas had a higher HBV load for a much longer period of time than the adenoma-free mice. Mechanisms underlying RNAi-mediated anti-adenoma effects in HBV transgenic mice Next, we investigated the mechanisms underlying RNAi-mediated liver adenoma suppression in HBV transgenic mice. We first measured serum ALT levels, and demonstrate that the HBV-S1-treated mice had significantly lower levels of serum ALT (39 ± 13 IU l À1 , P¼0.001 versus the saline group) than those treated with saline (101 ± 66 IU l À1 ), a level very similar to those of transgene negative littermates (37 ± 13 IU l À1 ; Figure 6a ), whereas the control GL2 shRNA treatment did not improve the ALT level (92 ± 49 IU l À1 , P¼0.44 versus the saline group). The normalization of serum ALT levels indicates that longterm RNAi treatment resulted in not only sustained HBV suppression, but also alleviation of liver damage. We then used immunohistochemistry to examine the expression of the nuclear proliferation marker Ki-67 in the livers to evaluate hepatocyte proliferation. Representative immunohistochemistry and quantification of Ki-67-positive cells are shown, respectively, in Figures 6b and c . HBV-S1 shRNA treatment greatly reduced the number of Ki-67-positive hepatocytes (15±5 cells per 100 hepatocytes) in transgenic mice compared with the saline (40 ± 8 cells per 100 hepatocytes, P¼0.000007) and GL2 shRNA controls (37±3 cells per 100 hepatocytes, P¼0.00006). Taken together with the ALT result, this data reflects that long-term inhibition of HBV gene expression and replication prevents liver injury and subsequent hepatocyte hyperproliferation, thus decreasing the chance of developing adenomas in aged transgenic mice.
DISCUSSION
The study of novel therapies for HBV-associated diseases using experimental approaches has been difficult because of the lack of appropriate animal models. Previous reports demonstrate that Figure 4 Time-course of the anti-HBV effects of dsAAV-delivered RNAi therapy in male ICR/HBV transgenic mice. (a) The schedule for dsAAV/ shRNA treatment. Age-and HBV-titer-matched male ICR/HBV transgenic mice were injected intravenously at the indicated times with different AAV serotypes encoding HBV-specific shRNA (HBV-S1) or an irrelevant shRNA (GL2) or with saline. In experiment 1, mice were injected at 6 weeks, 47 weeks and 62 weeks of age, respectively, with 1Â10 12 vg per mouse of dsAAV8, dsAAV9 or dsAAV7 vectors. In experiment 2, mice were treated with dsAAV8 at 6 weeks of age, followed by dsAAV9 at 62 weeks of age, both at a dose of 3.3Â10 13 vg per kg. The result for the HBV suppression effect in (b) experiment 1 (n¼4 for the HBV-S1 group, n¼4 for the GL2 group and n¼5 for the saline group) and (c) experiment 2 (n¼7 for the HBV-S1 group, n¼5 for the GL2 group and n¼11 for the saline group) is shown. Serum HBV DNA levels in each group were analyzed at the indicated times and are displayed as the mean ± s.d. transgenic mice of whole HBV genome produce intact HBV but do not manifest pathological changes or the development of liver tumors. 15, [19] [20] [21] In this study, we report that ICR/HBV mice, unlike other whole genome HBV transgenic mice, progressively display some key histopathological features of chronic HBV infection and eventually developed multiple hyperplastic nodules resembling hepatocellular adenomas in the majority of mice. Furthermore, we demonstrate that long-term suppression of HBV in ICR/HBV by therapeutic RNAi resulted in a decrease in liver cell injury and, more importantly, in overall liver adenoma occurrence rate. Our data suggest that long-term expression of the therapeutic RNAi might be a safe and effective therapy for preventing liver cancer development in chronic HBV patients. It is generally believed that HBV-induced liver injury is not caused by the virus itself but rather by the cellular immune response to infected hepatocytes, a conclusion supported by studies in transgenic mice carrying the whole HBV genome, 15, [19] [20] [21] [22] HBV-infected chimpanzees 23, 24 and chronic HBV patients. 1, 25 In contrast to these Figure 5 The anti-adenoma effect of RNAi therapy in male ICR/HBV transgenic mice. (a) Both sets of ICR/HBV mice treated with dsAAV-delivered shRNA as described in Figure 4 (experiments 1 and 2) were killed at 18 months of age. Age-and sex-matched transgene negative littermates (n¼8) were included as controls. Adenoma incidence (upper panel) and liver/body weight ratio, expressed as a percentage (mean ± s.d., lower panel) in each group (combined results for the two experiments, n¼11 for the HBV-S1 group, n¼7 for the GL2 group, and n¼16 for the saline group). Two mice in the GL2 group of experiment 1 of Figure 4 previous reports, our data demonstrated that clear liver injury evidenced by the increase in serum ALT levels ( Figure 2a ) and histopathological changes (Figure 2b ) developed in our ICR/HBV mice. During the 18-month experimental period, we did not observe detectable anti-HBsAg and anti-HBV e antigen antibodies in the serum, even after long-term RNAi-mediated suppression of HBV and HBV proteins, nor mononuclear cell infiltration in the liver, suggesting that the liver injury developed in ICR/HBV mice was not likely to be mediated by the anti-HBV immune reaction. Our result is consistent with recent findings which demonstrate that HBV by itself can generate cytopathic effect in a human hepatocyte-transplanted immunodeficient mouse model, and, more importantly, that the severity of liver disease was positively correlated with the extent and duration of HBV infection. 16, 26 The HBV-associated liver injury seen in the ICR/HBV model, similar to that in chronic HBV patients, takes a long time to establish, beginning at about 10 months of age then gradually becomes more severe. Compared with similar whole genome HBV transgenic mice, which do not develop liver injury, 15, [19] [20] [21] 27 our ICR/HBV mice produced much higher levels of serum HBV for a much longer time (up to at least 2 years of age). But we cannot rule out the possibility that the different genetic background of HBV transgenic mice used in our and other studies might affect the development of liver pathogenesis. It should also be noted that, in a normal physiological condition, cellular immune responses are likely to have a more dominant role in promoting HBV-associated liver injury and hepatocarcinogenesis, as suggested by the fact that chronic liver inflammation, induced by adoptively transferred splenocytes from HBsAg-immunized mice, was required for HCC development in a lineage of transgenic mice expressing a nontoxic level of HBV large surface protein. 17 In addition to the hepatic injury, 470% of male ICR/HBV mice spontaneously developed multiple liver nodules at 18 months of age (Figures 3a and b) . We postulate that prominent and sustained liver injury caused by the accumulation of large amounts of HBV and/or its gene products stimulated regeneration of hepatocytes, which eventually led to liver nodule formation. Histopathological examination of nodules in these mice demonstrated pre-neoplastic features, including small cell dysplasia and hyperplastic regeneration (Figure 3b) . Nevertheless, these liver nodules lacked typical characteristics of HCC and were classified as premalignant hepatocellular adenoma. Although hepatocellular adenoma has not been reported to be related with chronic HBV infection in patients, several studies showed adenoma development in HBV transgenic mice following immune or chemical stimulations. 17, 22 Furthermore, progression of liver adenoma to HCC has been observed in HBV and other animal models. 28, 29 Accordingly, we suggest that longer periods of observation and possibly additional host factors are required for the adenomas to eventually proceed to more malignant stages. Unfortunately, the adenoma-bearing ICR/ HBV mice began to die at 18 months of age, preventing us from testing this hypothesis. We believe that that the adenoma development in our ICR/HBV mice is more likely caused by accumulation of large amounts of HBV virions and proteins in hepatocytes and the subsequent cell death and regeneration events rather than abnormal genetic alterations induced by HBV transgene integration. This conclusion is supported by the following observations. First, RNAi, through inhibition of HBV gene expression, can significantly reduce the incidence of adenoma. Second, female ICR/HBV mice, which produce 2.4-fold less HBV virions compared with male mice (Figure 1e) , has a lower liver adenoma rate (20%) compared with 470% in male mice. Third, our preliminary data showed that the male C57BL/6/HBV transgenic mice, obtained by backcrossing ICR/ HBV onto the C57BL/6 genetic background and produced 10-fold less HBV compared with male ICR/HBV, did not develop detectable liver nodules over the 18-month observation period. However, we cannot totally rule out the role of HBV transgene integration in the pathogenesis of ICR/HBV mice. A direct proof of it requires characterization of the HBV and host chromosome junctions, which is beyond the scope of this study.
Our finding that female ICR/HBV mice produced less HBV virions and lower liver adenoma rate than that of male mice is similar to the epidemiological reports in humans demonstrating that female HBV carriers tend to have lower HBV DNA levels and decreased HCC incidence compared with male HBV carriers. 3, 30 The difference is likely because of the influence of sex hormone on HBV gene expression and replication, supporting by a previous report demonstrating that HBV protein expression in male transgenic mice can be reduced by castration and be restored by testosterone supplement. 31 Recently, two androgen-responsive elements were identified within HBV enhancer I, which can be bound and activated by androgen stimulations, providing molecular evidence supporting that HBV expression can be directly regulated by sex hormones. 32 In ICR/HBV mice, the sustained HBV suppression caused by AAV-mediated RNAi therapy significantly alleviated liver injury, as indicated by the normalization of serum ALT levels (Figure 6a ), and reduced liver adenoma incidence from 470% in the control groups to 36% in the HBV-S1 shRNA-treated group (Figure 5a ). The antiadenoma effect of RNAi therapy was dependent on the level and duration of HBV expression (Figure 5c ), as animals that were less responsive to RNAi therapy and/or had a rapid HBV rebound still had a higher risk of developing liver adenomas (Figure 5c ), although their size was much smaller than that in control animals (Figure 5b ). These results strongly support the hypothesis that effective long-term control of HBV levels might benefit chronic HBV patients by preventing severe hepatic complications, including cirrhosis and HCC, as revealed by several recent clinical studies of antiviral drug therapy. 5, 33, 34 In addition, our findings indicate that the ICR/HBV is a clinical relevant animal model for chronic HBV infection regarding evaluation of pathogenesis and therapeutics.
The molecular mechanism by which RNAi therapy prevents HBV-mediated adenoma formation in ICR/HBV mice is yet to be determined. There is evidence that HBV DNA and/or its gene products contribute to tumorigenesis. In transgenic mouse studies, overexpression and accumulation of the large PreS1/S2/S HBV envelope protein using an albumin promoter leads to the development of hepatocellular adenomas and carcinomas. 35, 36 On the other hand, the role of HBV X protein in hepatic carcinogenesis is more controversial, as transgenic mice expressing HBV X protein under the authentic promoter or an albumin promoter developed HCC in some studies, 37, 38 but not in others. 39 Our data demonstrate that AAV-based RNAi therapy provides a convenient and powerful method to achieve sustained marked suppression of HBV DNA and viral proteins and consequently to prevent liver damage and the occurrence and progression of liver adenomas. Further development and studies of the mechanism of action will be forthcoming in the future.
MATERIALS AND METHODS Animals
The generation of HBV transgenic mice on an ICR background has been reported previously. 13 These mice contain a 1.3-fold HBV genome (genotype D, serotype ayw) expressing HBV pregenomic and messenger RNAs under the control of the promoter and enhancer regulatory elements of the virus. 40 The Tg[HBV1.3]24-3 line was used in this study, as it produces the highest and most stable HBV titers. ICR/HBV mice were maintained in the hemizygous state by mating with wild-type ICR mice purchased from BioLASCO Taiwan Co. (Ilan, Taiwan). Transgene-positive mice were selected by screening for serum HBsAg and HBV DNA as described below. All animals were housed in a specificpathogen-free environment in the animal facility of the Institute of Biomedical Sciences, Academia Sinica. All experimental procedures were in compliance with Academia Sinica Institutional Animal Care and Use Committee and Council of Agriculture Guidebook for the Care and Use of Laboratory Animals.
Clinical samples
Human serum specimens were collected from chronic HBV patients who tested positive for HBsAg. This study was conducted with the approval of the Ethics Boards of the National Taiwan University Medical School and Taipei Veterans General Hospital.
Analysis of HBV DNA, RNA and proteins
Serum HBsAg and HBV e antigen were measured using enzyme-linked immunoassays (General Biologicals Corporation, Hsin-Chu, Taiwan). Serum HBV DNA was quantified by hybridization probe-based real-time PCR (LightCycler FastStart; Roche Diagnostics, Mannheim, Germany) as described. 14 Tissue HBV DNA and RNA were analyzed, respectively, by Southern and Northern blot analysis. 14 Expression of tissue HBV core antigen was detected by immunohistochemical staining of paraffin-embedded tissues as described previously. 13 
Measurement of ALT

Histological analysis
Liver histology, weight and nodules were examined when the mice were killed. Liver sections were fixed in 4% paraformaldehyde in phosphate-buffered saline, embedded in paraffin, sectioned (5 mm) and stained with hematoxylin and eosin. The sections were mounted and observed by light microscopy. Intracellular nucleocapsid particles were analyzed as described previously. 15 In brief, liver sections were fixed in 4% paraformaldehyde containing 0.1% glutaraldehyde in phosphate-buffered saline and then postfixed in 1% OsO 4 . After dehydration, embedding and microsectioning, the sections were mounted and stained with uranyl acetate and lead citrate. Grids were imaged with a JEM 1200EX electron microscope (JEOL, Tokyo, Japan).
AAV vector preparation and animal experiments
The production and quantification of double-stranded dsAAV7, dsAAV8 and dsAAV9 vectors, which contain the H1 promoter and a shRNA-encoding sequence (either the HBV-specific HBV-S1 or firefly luciferase-specific GL2) have been described previously. 14 The physical vector titer was measured by quantitative PCR using SYBR Green reaction mix (Roche Diagnostics). 13 Ageand HBV-titer-matched male HBV transgenic mice were intravenously injected with various AAV vectors as indicated in Figure 4a at 1Â10 12 vg per mouse or 3.3Â10 13 vg kg À1 . Serum samples were collected at the indicated time points to measure HBV DNA and HBsAg as described above. Mice were killed at 18 months of age to examine liver histology and liver adenoma incidence.
Hepatocyte proliferation
Paraffin-embedded liver sections were analyzed by immunohistochemistry using rabbit anti-mouse Ki-67 antibody (dilution 1:200; Abcam, Cambridge, MA, USA) and horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (dilution 1:400; Jackson ImmunoResearch, West Grove, PA, USA) The labeling index for each sample was determined by counting the numbers of Ki-67-positive nuclei per 100 hepatocytes.
Statistics
All data was analyzed for significance by Student's t-test or w 2 . A P-value of o0.05 was considered significant.
